A Survey of the Conditions on Pharmacoeconomic Studies at the Pharmaceutical Companies in Japan
10.3820/jjpe1996.6.49
- VernacularTitle:わが国における製薬企業の薬剤経済学研究の実施状況に関する調査
- Author:
Hiroyuki SAKAMAKI
;
Nobuyasu HIROMORI
;
Yumiko ABURAYA
;
Keiko NAKAMURA
- Publication Type:Journal Article
- Keywords:
pharmacoeconomics;
pharmaceutical company;
drug price
- From:Japanese Journal of Pharmacoepidemiology
2001;6(1):49-58
- CountryJapan
- Language:Japanese
-
Abstract:
Objective : To identify the issues in conducting pharmacoeconomics (PE) studies at pharmaceutical companies in Japan.
Methods : A questionnaire survey on the conditions of PE studies was conducted for the pharmaceutical companies that are members in the Pharmaceutical Manufacturers Association of Tokyo. Seventy-seven of 94 member companies participated, an 82% response rate. The survey covered the following topics with regard to the companies : the number of applications of PE data for the new drug pricing process, the timing and phases to conduct a PE analysis, a recognition of the necessity for PE analysis, and issues for conducting optimum PE analysis.
Results : Out of 77 responding companies, 36 companies (47%) answered that they conduct PE analysis at their regulatory affair department in order to submit supplemental applications for the drug pricing process to the Ministry of Health, Labor and Welfare. However, only 42% companies of approved drugs since April 1997 were actually submitted with PE data for the drug pricing review. Seventy-seven percent of companies recognized the necessity for PE analysis for the drugs. On the other hand, they did not perceive PE as a useful tool for negotiating drug prices with the Japanese government. Major issues for PE analysis to be conducted are ; lack of Japanese guidelines and epidemiological databases, lack of transparency in the method which reflects the data for the policy making, and lack of companies'initiative.
Conclusion : Establishment of a Japanese guideline for PE studies will be important for companies to conduct accurate and reliable PE studies. The Japanese government should disclose the process of using the PE data for policy making. At the same time, it is necessary for the companies to be more spontaneous in their PE studies.
